Navigation Links
Aeras-led research consortium receives FDA support
Date:10/4/2010

Rockville, MD, USA (October 4, 2010) The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding. The project is anticipated to cost $785,940 over three years.

"We are grateful for this show of support from the Food and Drug Administration for TB vaccine research," said Thomas G. Evans, MD, Chief Scientific Officer of the Aeras Global TB Vaccine Foundation. "Functional and biologically relevant immunological responses that correlate with vaccine efficacy remain elusive for tuberculosis so we are fortunate to be working with leaders in bioassay research to tackle this essential component of TB vaccine development."

The global TB epidemic continues to grow more complex and difficult to treat. The currently available TB vaccine called Bacille Calmette-Gurin has limited efficacy in preventing all forms of TB. BCG was developed before modern biotechnological advances and its method of eliciting immune response is not fully understood by researchers. Currently, there are 10 investigational TB vaccines designed as boosters or potential replacements for the BCG vaccine currently undergoing or poised to enter clinical testing and many more in the product development pipeline.

To effectively assess these and future investigational TB vaccines, biomarkers correlated with vaccine effectiveness are needed. A biomarker would facilitate clinical studies of vaccines across research institutions, geographic locations and within different target age groups and populations, standardizing and streamlining the regulatory review of clinical trial data.

"The development of biomarkers, particularly those that measure bacteriocidal effects correlated with TB vaccine effectiveness, could help shorten timeframes for introducing new TB vaccines, as we work with regulatory agencies like the FDA to conduct clinical trials and approve new TB vaccines," said Michael Brennan, PhD, Senior Advisor for Global Affairs at Aeras.

The project aims to evaluate four mycobacterial growth inhibition assays that can be reproducibly transferred to other laboratories and to identify T-cell immune and antibody responses that may be associated with ex vivo growth inhibition and potentially with protective vaccines.

The consortium is comprised of researchers at the Aeras Global TB Vaccine Foundation; the Jenner Institute, University of Oxford; the South African Tuberculosis Vaccine Initiative of the University of Cape Town; Saint Louis University; and Albert Einstein College of Medicine.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras Global TB Vaccine Foundation
Source:Eurekalert

Related biology news :

1. McGill partners with leading Swiss neuroscience research group
2. Bonn researchers use light to make the heart stumble
3. Hebrew University research holds promise for development of new osteoporosis drug
4. Earlier, more accurate prediction of embryo survival enabled by Stanford research
5. Researchers engineer adult stem cells that do not age
6. Research becomes a reality for Rett syndrome through new funding
7. OU researchers selected by Navy
8. RIT receives federal grant to construct new sustainability research facility
9. Iowa State University researcher examines mosquito gene for new disease response
10. NIH awards Rutgers $47.5 million to advance groundbreaking research on protein structures
11. NIH Transformative Research Project Awards hasten innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... MA (PRWEB) , ... November 30, 2016 , ... ... light sources for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light ... highly successful Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance and ...
Breaking Biology Technology: